1399 related articles for article (PubMed ID: 10622295)
41. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
[TBL] [Abstract][Full Text] [Related]
42. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
Weinblatt ME; Kremer JM; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Fox RI; Jackson CG; Lange M; Burge DJ
N Engl J Med; 1999 Jan; 340(4):253-9. PubMed ID: 9920948
[TBL] [Abstract][Full Text] [Related]
43. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment.
Kim J; Ryu H; Yoo DH; Park SH; Song GG; Park W; Cho CS; Song YW
J Korean Med Sci; 2013 Dec; 28(12):1716-22. PubMed ID: 24339699
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
45. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
Smolen JS; Feist E; Fatenejad S; Grishin SA; Korneva EV; Nasonov EL; Samsonov MY; Fleischmann RM;
N Engl J Med; 2022 Aug; 387(8):715-726. PubMed ID: 36001712
[TBL] [Abstract][Full Text] [Related]
46. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
Keystone EC; Genovese MC; Klareskog L; Hsia EC; Hall ST; Miranda PC; Pazdur J; Bae SC; Palmer W; Zrubek J; Wiekowski M; Visvanathan S; Wu Z; Rahman MU;
Ann Rheum Dis; 2009 Jun; 68(6):789-96. PubMed ID: 19066176
[TBL] [Abstract][Full Text] [Related]
47. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.
Taylor PC; Quattrocchi E; Mallett S; Kurrasch R; Petersen J; Chang DJ
Ann Rheum Dis; 2011 Dec; 70(12):2119-25. PubMed ID: 21859685
[TBL] [Abstract][Full Text] [Related]
48. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
50. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
Smolen JS; Agarwal SK; Ilivanova E; Xu XL; Miao Y; Zhuang Y; Nnane I; Radziszewski W; Greenspan A; Beutler A; Baker D
Ann Rheum Dis; 2017 May; 76(5):831-839. PubMed ID: 28087506
[TBL] [Abstract][Full Text] [Related]
51. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
[TBL] [Abstract][Full Text] [Related]
52. Infliximab for the treatment of rheumatoid arthritis.
Blumenauer B; Judd M; Wells G; Burls A; Cranney A; Hochberg M; Tugwell P
Cochrane Database Syst Rev; 2002; 2002(3):CD003785. PubMed ID: 12137712
[TBL] [Abstract][Full Text] [Related]
53. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
Visvanathan S; Wagner C; Smolen J; St Clair EW; Hegedus R; Baker D; Keenan G
Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
[TBL] [Abstract][Full Text] [Related]
54. Adalimumab: a review of its use in rheumatoid arthritis.
Bang LM; Keating GM
BioDrugs; 2004; 18(2):121-39. PubMed ID: 15046527
[TBL] [Abstract][Full Text] [Related]
55. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
56. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Emery P; Keystone E; Tony HP; Cantagrel A; van Vollenhoven R; Sanchez A; Alecock E; Lee J; Kremer J
Ann Rheum Dis; 2008 Nov; 67(11):1516-23. PubMed ID: 18625622
[TBL] [Abstract][Full Text] [Related]
57. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
Smolen JS; Weinblatt ME; Sheng S; Zhuang Y; Hsu B
Ann Rheum Dis; 2014 Sep; 73(9):1616-25. PubMed ID: 24699939
[TBL] [Abstract][Full Text] [Related]
58. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.
Stamm TA; Machold KP; Aletaha D; Alasti F; Lipsky P; Pisetsky D; Landewe R; van der Heijde D; Sepriano A; Aringer M; Boumpas D; Burmester G; Cutolo M; Ebner W; Graninger W; Huizinga T; Schett G; Schulze-Koops H; Tak PP; Martin-Mola E; Breedveld F; Smolen J
Arthritis Res Ther; 2018 Aug; 20(1):174. PubMed ID: 30092827
[TBL] [Abstract][Full Text] [Related]
59. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J;
Lancet; 2012 May; 379(9827):1712-20. PubMed ID: 22464340
[TBL] [Abstract][Full Text] [Related]
60. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
